JP2019531328A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531328A5
JP2019531328A5 JP2019521065A JP2019521065A JP2019531328A5 JP 2019531328 A5 JP2019531328 A5 JP 2019531328A5 JP 2019521065 A JP2019521065 A JP 2019521065A JP 2019521065 A JP2019521065 A JP 2019521065A JP 2019531328 A5 JP2019531328 A5 JP 2019531328A5
Authority
JP
Japan
Prior art keywords
antigen
domain
receptor
polypeptide
car according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019521065A
Other languages
English (en)
Japanese (ja)
Other versions
JP7100028B2 (ja
JP2019531328A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/057474 external-priority patent/WO2018075820A2/en
Publication of JP2019531328A publication Critical patent/JP2019531328A/ja
Publication of JP2019531328A5 publication Critical patent/JP2019531328A5/ja
Priority to JP2022071498A priority Critical patent/JP2022109975A/ja
Application granted granted Critical
Publication of JP7100028B2 publication Critical patent/JP7100028B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019521065A 2016-10-20 2017-10-19 セレブロン系のヘテロ二量体化可能なキメラ抗原受容体 Active JP7100028B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022071498A JP2022109975A (ja) 2016-10-20 2022-04-25 セレブロン系のヘテロ二量体化可能なキメラ抗原受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662410822P 2016-10-20 2016-10-20
US62/410,822 2016-10-20
PCT/US2017/057474 WO2018075820A2 (en) 2016-10-20 2017-10-19 Cereblon-based heterodimerizable chimeric antigen receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022071498A Division JP2022109975A (ja) 2016-10-20 2022-04-25 セレブロン系のヘテロ二量体化可能なキメラ抗原受容体

Publications (3)

Publication Number Publication Date
JP2019531328A JP2019531328A (ja) 2019-10-31
JP2019531328A5 true JP2019531328A5 (cg-RX-API-DMAC7.html) 2021-06-10
JP7100028B2 JP7100028B2 (ja) 2022-07-12

Family

ID=62019560

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019521065A Active JP7100028B2 (ja) 2016-10-20 2017-10-19 セレブロン系のヘテロ二量体化可能なキメラ抗原受容体
JP2022071498A Pending JP2022109975A (ja) 2016-10-20 2022-04-25 セレブロン系のヘテロ二量体化可能なキメラ抗原受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022071498A Pending JP2022109975A (ja) 2016-10-20 2022-04-25 セレブロン系のヘテロ二量体化可能なキメラ抗原受容体

Country Status (8)

Country Link
US (2) US11331380B2 (cg-RX-API-DMAC7.html)
EP (2) EP3528851B1 (cg-RX-API-DMAC7.html)
JP (2) JP7100028B2 (cg-RX-API-DMAC7.html)
CN (1) CN109983027A (cg-RX-API-DMAC7.html)
CA (1) CA3041284A1 (cg-RX-API-DMAC7.html)
ES (1) ES2916335T3 (cg-RX-API-DMAC7.html)
TW (1) TWI781117B (cg-RX-API-DMAC7.html)
WO (1) WO2018075820A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
AU2014240083C1 (en) 2013-03-15 2019-10-24 Celgene Corporation Modified T lymphocytes
PT3618842T (pt) * 2017-05-01 2024-01-12 Juno Therapeutics Inc Combinação de uma terapia celular e de um composto imunomodulador
GB201710620D0 (en) 2017-07-03 2017-08-16 Glaxosmithkline Intellectual Property Ltd Targeted protein degradation
KR102656934B1 (ko) 2017-07-10 2024-04-16 셀진 코포레이션 항증식성 화합물 및 이의 사용 방법
CA3079407A1 (en) 2017-10-18 2019-04-25 Novartis Ag Compositions and methods for selective protein degradation
BR112020008638A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
KR102813281B1 (ko) 2018-05-23 2025-05-28 셀진 코포레이션 병용 사용을 위한 bcma 및 cd3에 대한 항증식성 화합물 및 이중특이성 항체
AU2019318135A1 (en) * 2018-08-10 2021-03-04 Sangamo Therapeutics France New car constructs comprising TNFR2 domains
EP3860643A1 (en) * 2018-10-05 2021-08-11 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3876958A1 (en) * 2018-11-08 2021-09-15 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
WO2020116686A1 (ko) * 2018-12-06 2020-06-11 고려대학교 산학협력단 인간 항-antxr 키메라 항원 수용체 및 이의 용도
WO2021030153A2 (en) * 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
CN114867471A (zh) * 2019-10-18 2022-08-05 北卡罗来纳大学教堂山分校 使用多种配体缀合的纳米颗粒结合nk细胞上的受体治疗癌症的方法和组合物
CA3168456A1 (en) * 2020-01-20 2021-07-29 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, and pharmaceutical composition and use thereof
WO2022109611A1 (en) 2020-11-20 2022-05-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
JP2024526182A (ja) * 2021-06-25 2024-07-17 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US5783404A (en) 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
EP1171596A1 (en) 1999-04-16 2002-01-16 Celltech Therapeutics Limited Synthetic transmembrane components
ATE528406T1 (de) 1999-04-29 2011-10-15 Gbp Ip Llc Verfahren und mittel zur herstellung von sicheren,rekombinanten lentivirusvektoren mit hohem titer
JP5312721B2 (ja) 2000-11-07 2013-10-09 シティ・オブ・ホープ Cd19特異的再指向免疫細胞
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
AUPR617901A0 (en) 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
WO2004032857A2 (en) 2002-10-08 2004-04-22 Immunomedics, Inc. Antibody therapy
US7541442B2 (en) 2003-05-30 2009-06-02 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
US20050118185A1 (en) 2003-06-18 2005-06-02 Cell Center Cologne Gmbh Recombinant immunoreceptors
KR101531400B1 (ko) 2003-06-27 2015-06-26 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
CN1946425B (zh) 2004-02-27 2012-10-03 免疫系统治疗有限公司 B细胞疾病的靶
WO2007044033A2 (en) 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
ES2595307T3 (es) 2007-01-31 2016-12-29 Yeda Research And Development Company Limited Células T reguladoras redirigidas, modificadas genéticamente y su uso en la supresión de enfermedades autoinmunes e inflamatorias
JP2012501180A (ja) 2008-08-26 2012-01-19 シティ・オブ・ホープ T細胞の抗腫瘍エフェクター機能増進のための方法および組成物
BRPI1005984A2 (pt) 2009-02-23 2016-10-04 Glenmark Pharmaceuticals Sa anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
AU2011268110B2 (en) 2010-06-19 2016-05-19 Memorial Sloan-Kettering Cancer Center Anti-GD2 antibodies
WO2012033885A1 (en) 2010-09-08 2012-03-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered gd2-specific t cells
WO2012050374A2 (en) 2010-10-13 2012-04-19 Innocell, Inc. Immunotherapy for solid tumors
AU2011319727B2 (en) 2010-10-27 2016-06-30 Baylor College Of Medicine Chimeric CD27 receptors for redirecting T cells to CD70-positive malignancies
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9402865B2 (en) 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
BR112013024395B1 (pt) 2011-03-23 2021-10-26 Fred Hutchinson Cancer Research Center Composições adotivas de imunoterapia celular e método para fabricação da dita composição
ES2649967T3 (es) 2011-04-08 2018-01-16 Baylor College Of Medicine Inversión de los efectos del microentorno tumoral utilizando receptores quiméricos de citocinas
PT3459560T (pt) 2011-04-08 2021-05-24 Us Health Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização dos mesmos para o tratamento de cancro
AU2012308205A1 (en) 2011-09-16 2014-03-13 The Trustees Of The University Of Pennsylvania RNA engineered T cells for the treatment of cancer
RU2644243C2 (ru) 2011-10-20 2018-02-08 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы к cd22
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
WO2013067492A1 (en) 2011-11-03 2013-05-10 The Trustees Of The University Of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
JP6318152B2 (ja) 2012-06-29 2018-04-25 セルジーン コーポレイション セレブロン関連タンパク質を利用して薬物効能を決定する方法
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
KR102417657B1 (ko) 2013-02-06 2022-07-07 안트로제네시스 코포레이션 개선된 특이성을 갖는 변경된 t 림프구
PL3300745T3 (pl) * 2013-02-15 2020-03-31 The Regents Of The University Of California Chimeryczny receptor antygenowy i sposoby jego zastosowania
CA2912172A1 (en) 2013-06-05 2014-12-11 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
WO2015017214A1 (en) * 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
US10272117B2 (en) * 2014-02-24 2019-04-30 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
EP4649963A2 (en) * 2014-04-14 2025-11-19 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
NZ729046A (en) 2014-08-12 2022-07-29 Celgene Corp Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
AU2016222887B2 (en) * 2015-02-24 2022-07-14 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2019531328A5 (cg-RX-API-DMAC7.html)
JP2022109975A5 (cg-RX-API-DMAC7.html)
US20220370580A1 (en) Cereblon-based heterodimerizable chimeric antigen receptors
KR102879284B1 (ko) 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도
Felices et al. Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells
CN111886012A (zh) 细胞疗法与γ分泌酶抑制剂的组合
JP2017513818A5 (cg-RX-API-DMAC7.html)
US20230095912A1 (en) Composition and Methods for Selective Degradation of Engineered Proteins
JPWO2020047452A5 (cg-RX-API-DMAC7.html)
WO2020057641A1 (zh) 表达有趋化因子的细胞及用途
JP2020535796A5 (cg-RX-API-DMAC7.html)
US12459983B2 (en) Engineered immune cells with receptor signal strength modulated by a hinge
JPWO2021173985A5 (cg-RX-API-DMAC7.html)
JPWO2019165116A5 (cg-RX-API-DMAC7.html)
KR20210111244A (ko) 태반-유래 동종이계 car-t 세포 및 이의 용도
JPWO2023015283A5 (cg-RX-API-DMAC7.html)
JPWO2023196994A5 (cg-RX-API-DMAC7.html)
WO2024254772A1 (zh) 工程化的滋养细胞及其用途
RU2024129913A (ru) Клетки, имеющие нацеленный на солидную опухоль каркас, и их применение
JPWO2023196982A5 (cg-RX-API-DMAC7.html)
HK40014026B (en) Cereblon-based heterodimerizable chimeric antigen receptors
HK40014026A (en) Cereblon-based heterodimerizable chimeric antigen receptors